Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
NanoViricides Inc (NNVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/05/2025: NNVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -79.89% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.83M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 485707 | Beta 0.97 | 52 Weeks Range 1.03 - 3.59 | Updated Date 11/13/2024 |
52 Weeks Range 1.03 - 3.59 | Updated Date 11/13/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Earnings Date
Report Date 2025-02-12 | When After Market | Estimate - | Actual -0.1391 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.81% | Return on Equity (TTM) -63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15958352 | Price to Sales(TTM) - |
Enterprise Value 15958352 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 13945600 | Shares Floating 13972210 |
Shares Outstanding 13945600 | Shares Floating 13972210 | ||
Percent Insiders 4.07 | Percent Institutions 9.72 |
AI Summary
Company Profile:
NanoViricides Inc is a clinical stage pharmaceutical company based in Shelton, Connecticut, focused on developing nanomedicines for the treatment of viral diseases. The company was founded in 2005 and has since been dedicated to advancing its proprietary nanomedicine platform to create innovative antiviral therapies. NanoViricides has a diverse pipeline of drug candidates targeting a range of viral infections, including influenza, herpes, Ebola, and COVID-19.
The core business areas of NanoViricides Inc revolve around research and development of novel nanomedicines, conducting clinical trials to evaluate the safety and efficacy of its drug candidates, securing regulatory approvals for commercialization, and ultimately bringing these innovative therapies to market to address unmet medical needs.
The leadership team of NanoViricides Inc is led by Dr. Anil Diwan, the company's co-founder, President, and Chairman. Dr. Diwan is a seasoned biotech entrepreneur with a background in chemical engineering and pharmaceutical sciences. The corporate structure of NanoViricides includes experienced executives, scientists, and clinicians who contribute to the company's R&D efforts, clinical operations, regulatory affairs, and strategic partnerships.
Top Products and Market Share:
NanoViricides Inc's lead product is NV-CoV-2, a COVID-19 treatment candidate that is currently undergoing clinical trials. The company's other drug candidates include NV-INF-1 for influenza, NV-HSV-1 for herpes infections, and NV-EBOV for Ebola virus disease.
In terms of market share, NanoViricides Inc is a small-cap biopharmaceutical company with limited commercial presence compared to larger pharmaceutical companies. However, the company's innovative nanomedicine platform and promising drug candidates have garnered interest from investors and the scientific community.
Total Addressable Market:
The total addressable market for NanoViricides Inc is significant, given the global prevalence of viral diseases and the increasing need for effective antiviral therapies. The COVID-19 pandemic has further highlighted the importance of developing novel treatments for infectious diseases, creating opportunities for companies like NanoViricides to address these unmet medical needs.
Financial Performance:
NanoViricides Inc's financial performance has been primarily driven by investments in research and development activities to advance its drug pipeline. Recent financial statements show modest revenues, limited net income due to ongoing R&D expenses, and a fluctuating stock price. The company's profit margins and earnings per share (EPS) are influenced by its clinical trial progress, regulatory milestones, and market expectations.
Dividends and Shareholder Returns:
NanoViricides Inc does not currently pay dividends as reinvesting profits into its R&D initiatives is a priority. Shareholder returns are subject to market dynamics, clinical trial outcomes, regulatory approvals, and partnerships that impact the company's stock performance over time.
Growth Trajectory:
NanoViricides Inc has demonstrated growth potential through its pipeline expansion, technology advancements, and clinical progress. The company's future growth projections are contingent on successful clinical outcomes, regulatory approvals, commercialization strategies, and market opportunities.
Market Dynamics:
The pharmaceutical industry NanoViricides Inc operates in is dynamic, characterized by evolving regulatory requirements, technological innovations, and competitive landscapes. The demand for antiviral therapies, market trends, and healthcare challenges influence the company's positioning and growth prospects within the industry.
Competitors:
Key competitors of NanoViricides Inc in the antiviral drug development space include Gilead Sciences (GILD), Moderna Inc (MRNA), and Johnson & Johnson (JNJ). NanoViricides faces competition from larger pharmaceutical companies with established portfolios, research capabilities, and market presence. The company's competitive advantages include its nanomedicine platform, targeted approach to viral infections, and potential to address unmet medical needs in specific disease areas.
Potential Challenges and Opportunities:
Key challenges for NanoViricides Inc include securing regulatory approvals, funding R&D activities, navigating clinical trial complexities, and competing with established players in the pharmaceutical industry. However, opportunities exist in expanding its pipeline, forging strategic partnerships, entering new therapeutic areas, and contributing to the global fight against infectious diseases.
Recent Acquisitions (last 3 years):
NanoViricides Inc has not made any significant acquisitions in the last three years, as the company's focus has been on advancing its internal drug development programs and clinical initiatives to bring novel antiviral therapies to market.
AI-Based Fundamental Rating:
Evaluation of NanoViricides Inc's stock fundamentals using an AI-based rating system would rate the company's prospects as moderate, reflecting the potential upside of its innovative nanomedicine platform, clinical pipeline, and market opportunities. However, factors such as regulatory risks, competition, and funding challenges could impact the company's overall rating.
Sources and Disclaimers:
Sources used for gathering data for this analysis include the company's official website, financial reports, press releases, industry publications, and market research reports. This overview is intended for informational purposes only and should not be construed as investment advice. Investors are advised to conduct their research and consult with financial advisors before making investment decisions based on this information.
About NanoViricides Inc
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com | ||
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.